2008
Exactech Says Patent-Pending Optetrak® CR Slope™ Knee System Demonstrates Excellent Performance, Broad Applicability In Early Clinical Results
GAINESVILLE, Fla. -- December 17, 2008 -- Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, said today that surgeons are experiencing excellent early results with its new Optetrak® CR Slope™ knee system. Introduced in Q4 2008, the patent-pending CR Slope design builds on the company’s flagship Optetrak knee system.
Exactech Q3 Revenue Up 27% to $37.9M; Net Income $2.1M
GAINESVILLE, Fla. -- October 28, 2008 -- Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, announced today that revenue for the third quarter of 2008 increased 27% to $37.9 million from $30.0 million in the third quarter of 2007. Diluted earnings per share for the quarter were $0.16 based on net income of $2.1 million. This compares with net income of $2.5 million or $0.21 diluted EPS a year ago. As previously announced, the net income includes pre-tax legal expenses and costs of $1.2 million related to the ongoing Department of Justice inquiry.
Exactech Updates Third Quarter Financial Guidance. Announces Q3 Earnings and Conference Call
GAINESVILLE, Fla. -- October 14, 2008 -- Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, said today that revenue for the quarter, which ended September 30, will be approximately $37.9 million, an increase of 26% and within the previously announced range. Earnings for the third quarter of 2008 will be below the company’s original estimates of $0.21-$0.23 diluted earnings per share and will be approximately $0.15 diluted earnings per share due to higher than expected legal expenses in the quarter of approximately $1.4 million, or $0.07 per share after taxes.
Pro golfer swings by Exactech
A pro golfer with a piece of a local company inside him gave back a little of himself to the company last week. Peter Jacobsen visited Exactech Inc. to tour the plant, sign autographs and show off how well his new Optetrak knee made by Exactech is working.
Exactech to Present to Investors at Baird’s 2008 Small Cap Healthcare Conference
GAINESVILLE, Fla. -- September 8, 2008 -- Exactech Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, will present at Baird's 2008 Small Cap Healthcare Investor Conference on September 10 in New York.
Exactech to Present at the 2008 Noble Financial Equity Conference on August 18
GAINESVILLE, Fla. -- August 5, 2008 -- Exactech Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, will present at the Fourth Annual Noble Financial Equity Conference. The two-day conference will showcase 150 small cap public companies at the Loews Lake Las Vegas Resort, Nevada.
Exactech Q2 Revenue Up 38% to $43.7M; Net Income $3.0M vs $1.4M
GAINESVILLE, Fla. -- July 30, 2008 -- Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, announced today that revenue for the second quarter of 2008 increased 38% to $43.7 million from $31.6 million in the second quarter of 2007. Diluted earnings per share for the quarter was $0.24 based on net income of $3.0 million. This compares with net income of $1.4 million or $0.12 diluted EPS a year ago.
Exactech Awarded National Contract from HealthTrust Purchasing Group for Orthopaedic Products
GAINESVILLE, Fla. -- July 29, 2008 -- Exactech Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, announced today it has been awarded a national purchasing contract by HealthTrust Purchasing Group (HealthTrust). This contract will cover the Equinoxe® Shoulder product line. The award is a three-year agreement that goes into effect August 1, 2008.
Exactech Announces Q2 Earnings and Conference Call
GAINESVILLE, Fla. -- July 16, 2008 -- Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, will release its second quarter earnings on Wednesday, July 30, after the market closes.
Exactech Joins Russell 3000 Index
GAINESVILLE, Fla. -- July 1, 2008 -- Exactech Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, announced today it was added to the broad-market Russell 3000 Index when Russell Investments reconstituted its comprehensive set of U.S. and global equity indexes. The Russell 3000 Index measures the performance of the 3,000 largest U.S. companies based on total market capitalization. The final membership list for the Russell 3000 has been posted at www.russell.com/Indexes/membership/default.asp.
Exactech Awarded National Contract from HealthTrust Purchasing Group
GAINESVILLE, Fla. -- June 18, 2008 -- Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, announced today it was awarded a national purchasing contract by HealthTrust Purchasing Group, LP (HealthTrust). This contract will include primary and revision hip and knee implants, as well as InterSpace® cement spacers. The award is a five-year agreement that goes into effect July 15th.
Exactech Signs New $40 Million Revolving Line of Credit
GAINESVILLE, Fla. -- June 16, 2008 -- Exactech Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, announced today it has signed a new $40 million syndicated line of credit.
Exactech Expands Total Hip Replacement Offerings with Full Market Release of Novation® Crown Cup System
GAINESVILLE, Fla. -- June 13, 2008 -- Exactech Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, announced today the full-market release of the Novation® Crown Cup® Acetabular System, the latest component of the Novation Comprehensive Hip System.
Exactech Announces Leadership Promotions
GAINESVILLE, Fla. -- June 3, 2008 -- Exactech Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, announced today several key leadership promotions.
Exactech Completes Previously Announced Sale of Common Stock
GAINESVILLE, Fla. -- May 14, 2008 -- Exactech Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, announced today that it has closed its previously announced sale of 877,391 shares of its common stock to certain institutional investors at a price of $23.00 per share. The sale resulted in gross proceeds of approximately $20.2 million and net proceeds of approximately $18.8 million after offering expenses and placement agency fees. Exactech offered the shares pursuant to an effective registration statement previously filed with the Securities and Exchange Commission.
Exactech Announces Sale of Common Stock Resulting in $20.2 Million in Gross Proceeds
GAINESVILLE, Fla. -- May 9, 2008 -- Exactech Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, announced today that it has entered into definitive agreements with certain institutional investors to sell 877,391 shares of its common stock at a price of $23.00 per share, resulting in gross proceeds of approximately $20.2 million and net proceeds of approximately $18.8 million after offering expenses and placement agency fees. Exactech offered the shares pursuant to an effective registration statement previously filed with the Securities and Exchange Commission. The offering is expected to close on or before May 14, 2008 and is subject to certain closing conditions.
Exactech Q1 Revenue Increases 34% to $39.8 Million
GAINESVILLE, Fla. -- April 29, 2008 -- Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, announced today revenue of $39.8 million for the first quarter of 2008, an increase of 34% compared to $29.6 million for the first quarter of 2007. Net income for the quarter was $2.8 million, or $0.23 per diluted share, a gain of 49% from the $1.9 million, or $0.16 per diluted share, in the same quarter a year ago. First quarter diluted earnings per share included a gain of $0.03 due to a forward currency call option and a loss of $0.01 per share due to Exactech’s minority investment in Altiva prior to the acquisition.
Exactech Increases Q1 and FY’08 Financial Guidance
GAINESVILLE, Fla. -- April 10, 2008 -- Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, announced today that it expects to report revenue of approximately $40.0 million for the first quarter of 2008, an increase of 35% compared to $29.6 million for the first quarter of 2007. Diluted earnings per share for the first quarter is expected to range from $0.22 to $0.24 compared with $0.16 diluted earnings per share in the same quarter a year ago. First quarter earnings include a gain of $0.03 due to a forward currency call option.
Exactech Closes France Medica Acquisition
GAINESVILLE, Fla. -- April 7, 2008 -- Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, announced today that, effective April 1, 2008, it closed on the acquisition of the stock and assets of France Medica SAS, a French importer and distributor of orthopaedic products and surgical supplies.
Exactech Names Industry Veteran Daniel Berdat as VP of International Sales and Marketing
GAINESVILLE, Fla. -- April 1, 2008 -- Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, announced today the appointment of Daniel Berdat as Vice President of International Sales and Marketing, effective April 1.
